Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

The severity of left ventricular diastolic dysfunction affects risk for incident stroke and transient ischemic attack, as well as major bleeding.

There is decreased risk for MACE, stroke, and mortality in patients with newly diagnosed atrial fibrillation who regularly use statins.

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

The following is a summary of “Factors associated with the detection of atrial fibrillation in patients with embolic stroke ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

Hypertension, atrial fibrillation, and smoking are strongly associated with an increased risk for severe vs nonsevere stroke.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...